Search Results for "adenosine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for adenosine. Results 31 to 38 of 38 total matches.
See also: Adenocard
Drugs for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
with aspirin or the adenosine diphosphate receptor antagonist clopidogrel (Plavix – Medical Letter 1998; 40:59 ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
a monoamine oxidase type B (MAO-B) inhibitor, or
the adenosine A2A receptor antagonist istradefylline ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
OF ACTION — Mavacamten is a selective
inhibitor of cardiac myosin adenosine triphosphatase
(ATPase ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Drugs for Percutaneous Coronary Interventions
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
Clopidogrel (Plavix), a thienopyridine, inhibits adenosine diphosphate receptor-mediated platelet activity.
7 ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
% 384.40
ACL = adenosine triphosphate-citrate lyase; ER = extended-release; susp = suspension
1. FDA ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Antiviral Drugs
Treatment Guidelines from The Medical Letter • Mar 01, 2013 (Issue 127)
that requires diester hydrolysis for
conversion to tenofovir, a nucleotide analog of adenosine
5-monophosphate ...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
of cyclic adenosine monophosphate (cAMP),
which suppresses production of proinflammatory
cytokines ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
= adenosine triphosphate-citrate lyase; ASCVD = atherosclerotic cardiovascular disease; BCRP = breast cancer ...
View the Comparison Table: Some Lipid-Lowering Drugs